This may explain why some cancers, including mismatch repair proficient colorectal cancers, have exhibited poor responses to checkpoint inhibitor therapy and suggests that RASi could play a role in the treatment of CRC by modulating the immune infiltrate. This evidence concerns the gene MMP19 and colorectal cancer.